114 related articles for article (PubMed ID: 3803450)
21. Macrophage models of Gaucher disease for evaluating disease pathogenesis and candidate drugs.
Aflaki E; Stubblefield BK; Maniwang E; Lopez G; Moaven N; Goldin E; Marugan J; Patnaik S; Dutra A; Southall N; Zheng W; Tayebi N; Sidransky E
Sci Transl Med; 2014 Jun; 6(240):240ra73. PubMed ID: 24920659
[TBL] [Abstract][Full Text] [Related]
22. Intracellular activity of lysosomal glucosylceramidase measured with 4-nonylumbelliferyl beta-glucoside.
Bieberich E; Legler G
Biol Chem Hoppe Seyler; 1989 Aug; 370(8):809-17. PubMed ID: 2590464
[TBL] [Abstract][Full Text] [Related]
23. Glucocerebrosidase deficiency dramatically impairs human bone marrow haematopoiesis in an in vitro model of Gaucher disease.
Berger J; Lecourt S; Vanneaux V; Rapatel C; Boisgard S; Caillaud C; Boiret-Dupré N; Chomienne C; Marolleau JP; Larghero J; Berger MG
Br J Haematol; 2010 Jul; 150(1):93-101. PubMed ID: 20507316
[TBL] [Abstract][Full Text] [Related]
24. Changes in macrophage morphology in a Gaucher disease model are dependent on CTP:phosphocholine cytidylyltransferase alpha.
Kacher Y; Golan A; Pewzner-Jung Y; Futerman AH
Blood Cells Mol Dis; 2007; 39(1):124-9. PubMed ID: 17482853
[TBL] [Abstract][Full Text] [Related]
25. Animal and cellular models of Gaucher's disease. I. Refractoriness of thio analogs of glucocerebroside to enzymatic hydrolysis.
Quirk JM; Weis AL; Shapiro D; Brady RO
Biotechnol Appl Biochem; 1986 Feb; 8(1):96-100. PubMed ID: 3828086
[TBL] [Abstract][Full Text] [Related]
26. Glucosylceramide and glucosylsphingosine metabolism in cultured fibroblasts deficient in acid beta-glucosidase activity.
Sasagasako N; Kobayashi T; Yamaguchi Y; Shinnoh N; Goto I
J Biochem; 1994 Jan; 115(1):113-9. PubMed ID: 8188616
[TBL] [Abstract][Full Text] [Related]
27. Glucosylceramide and the level of the glucosidase-stimulating proteins.
Datta SC; Radin NS
Lipids; 1986 Nov; 21(11):702-9. PubMed ID: 3099116
[TBL] [Abstract][Full Text] [Related]
28. A lysosomal storage disorder in mice characterized by a dual deficiency of sphingomyelinase and glucocerebrosidase.
Pentchev PG; Gal AE; Booth AD; Omodeo-Sale F; Fouks J; Neumeyer BA; Quirk JM; Dawson G; Brady RO
Biochim Biophys Acta; 1980 Sep; 619(3):669-79. PubMed ID: 6257302
[TBL] [Abstract][Full Text] [Related]
29. A revised fluorometric assay for Gaucher's disease using conduritol-beta-epoxide with liver as the source of Beta-glucosidase.
Daniels LB; Glew RH; Radin NS; Vunnam RR
Clin Chim Acta; 1980 Sep; 106(2):155-63. PubMed ID: 6773704
[TBL] [Abstract][Full Text] [Related]
30. Gaucher disease. III. Substrate specificity of glucocerebrosidase and the use of nonlabeled natural substrates for the investigation of patients.
Choy FY; Davidson RG
Am J Hum Genet; 1980 Sep; 32(5):670-80. PubMed ID: 6775530
[TBL] [Abstract][Full Text] [Related]
31. Systemic inflammation in glucocerebrosidase-deficient mice with minimal glucosylceramide storage.
Mizukami H; Mi Y; Wada R; Kono M; Yamashita T; Liu Y; Werth N; Sandhoff R; Sandhoff K; Proia RL
J Clin Invest; 2002 May; 109(9):1215-21. PubMed ID: 11994410
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of neuronal mitochondrial complex I or lysosomal glucocerebrosidase is associated with increased dopamine and serotonin turnover.
de la Fuente C; Burke DG; Eaton S; Heales SJR
Neurochem Int; 2017 Oct; 109():94-100. PubMed ID: 28242245
[TBL] [Abstract][Full Text] [Related]
33. Lectin-specific targeting of lysosomal enzymes to reticuloendothelial cells.
Murray GJ
Methods Enzymol; 1987; 149():25-42. PubMed ID: 3695962
[TBL] [Abstract][Full Text] [Related]
34. Synthesis and evaluation of glucocerebrosidase inhibitory activity of anhydro deoxyinositols from (+)-epi- and (-)-vibo-quercitols.
Ogawa S; Uetsuki S; Tezuka Y; Morikawa T; Takahashi A; Sato K
Bioorg Med Chem Lett; 1999 Jun; 9(11):1493-8. PubMed ID: 10386923
[TBL] [Abstract][Full Text] [Related]
35. Bone marrow microenvironment in an in vitro model of Gaucher disease: consequences of glucocerebrosidase deficiency.
Lecourt S; Vanneaux V; Cras A; Freida D; Heraoui D; Herbi L; Caillaud C; Chomienne C; Marolleau JP; Belmatoug N; Larghero J
Stem Cells Dev; 2012 Jan; 21(2):239-48. PubMed ID: 21867425
[TBL] [Abstract][Full Text] [Related]
36. Glucosylceramide transfer from lysosomes--the missing link in molecular pathology of glucosylceramidase deficiency: a hypothesis based on existing data.
Elleder M
J Inherit Metab Dis; 2006 Dec; 29(6):707-15. PubMed ID: 17080304
[TBL] [Abstract][Full Text] [Related]
37. Correlation between enzyme activity and substrate storage in a cell culture model system for Gaucher disease.
Schueler UH; Kolter T; Kaneski CR; Zirzow GC; Sandhoff K; Brady RO
J Inherit Metab Dis; 2004; 27(5):649-58. PubMed ID: 15669681
[TBL] [Abstract][Full Text] [Related]
38. Active site directed inhibition of a cytosolic beta-glucosidase from calf liver by bromoconduritol B epoxide and bromoconduritol F.
Legler G; Bieberich E
Arch Biochem Biophys; 1988 Jan; 260(1):437-42. PubMed ID: 3124752
[TBL] [Abstract][Full Text] [Related]
39. Human acid beta-glucosidase: isolation and amino acid sequence of a peptide containing the catalytic site.
Dinur T; Osiecki KM; Legler G; Gatt S; Desnick RJ; Grabowski GA
Proc Natl Acad Sci U S A; 1986 Mar; 83(6):1660-4. PubMed ID: 3456607
[TBL] [Abstract][Full Text] [Related]
40. Osteocyte Alterations Induce Osteoclastogenesis in an In Vitro Model of Gaucher Disease.
Bondar C; Ormazabal M; Crivaro A; Ferreyra-Compagnucci M; Delpino MV; Rozenfeld PA; Mucci JM
Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28098793
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
